Ignite Creation Date:
2024-05-06 @ 8:12 AM
Last Modification Date:
2024-10-26 @ 11:57 AM
Study NCT ID:
NCT02686177
Status:
COMPLETED
Last Update Posted:
2021-06-15
First Post:
2016-02-15
Brief Title:
Effect of GLP-1 on Angiogenesis
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Effect of GLP-1 on Angiogenesis Angiosafe Type 2 Diabetes Study 1
Status:
COMPLETED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ANGIOSAFE 1
Brief Summary:
GLP-1 receptor agonists are introduced in the treatment of type 2 Diabetes T2D and their efficacy is documented However safety aspects are also important to evaluate with respect to micro and macrovascular complications associated with T2D Few studies have properly addressed the role of GLP-1-based therapies in regulating vascular integrity and angiogenesis The study evaluate the impact of one-month treatment Liraglutide on both ANGPT2 and ANGLPT4 levels and endothelial circulating progenitor cells angiogenesis biomarkers in type 2 diabetic patients
Detailed Description:
GLP-1 receptor agonists are introduced in the treatment of type 2 Diabetes T2D and their efficacy is documented Beside their therapeutic benefits direct cardiovascular effects have also been reported However safety aspects are also important to evaluate with respect to micro and macrovascular complications associated with T2D T2D patients treated with GLP-1 analogs may suffer from microvascular complications such as macular oedema and proliferative retinopathy characterized by excessive retinal angiogenesis Few studies have properly addressed the role of GLP-1-based therapies in regulating vascular integrity and angiogenesis The role of GLP-1 on endothelial cell EC growth EC integrity and angiogenesis thus needs to be characterized Our aim is to provide the proof of concept that agonists of GLP-1 regulate angiogenesis in humans and identify the underlying mechanisms The present project is the translational part of the ANR Angiosafe-T2D regarding clinical safety aspects of GLP-1 receptor agonists namely Liraglutide on angiogenesis
The study evaluate the impact of one-month treatment Liraglutide on both ANGPT2 and ANGLPT4 levels and endothelial circulating progenitor cells angiogenesis biomarkers in type 2 diabetic patients
The study evaluate the impact of one-month treatment Liraglutide on both ANGPT2 and ANGLPT4 levels and endothelial circulating progenitor cells angiogenesis biomarkers in type 2 diabetic patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2015-002930-35 | OTHER | IDRCB | None |